CTIC Capital Company Profile

Background

Overview

CTIC Capital is a Silicon Valley-based global healthcare consulting firm specializing in cross-border business development. Established in 2013, the firm offers a comprehensive suite of strategic advisory services to Biotech and MedTech companies worldwide. These services encompass corporate strategy, business development, asset licensing, mergers and acquisitions, capital formation, and financing advisory. With over 100 years of combined experience, the partners at CTIC Capital include company founders, CEOs, CFOs, investment bankers, venture capital and private equity investors, and financial advisors. The firm operates from multiple locations, including Palo Alto, San Francisco, Chicago, Shanghai, Hong Kong, and Taiwan. Collectively, they have completed over 100 transactions with a deal value exceeding $30 billion across more than 15 countries.

Mission and Vision

CTIC Capital's mission is to bridge the gap between the U.S. and China healthcare markets, facilitating the commercialization of technological innovations and supporting global aspirations of enterprises. The firm's vision is to be a trusted advisor in cross-border healthcare investment, leveraging its extensive networks and local expertise to drive growth and innovation in the biotech and medtech sectors.

Key Strategic Focus

Core Objectives

• Business Development and Licensing: Establishing extensive networks with business development and licensing heads, R&D executives, and key opinion leaders in both biopharma and medtech sectors.

• Capital Formation and Fundraising: Leveraging a network of over 500 healthcare-focused venture capital firms and pharmaceutical companies across geographies to facilitate efficient and effective capital formation.

• Company Creation and Geographic Expansion: Assisting in launching new companies with cutting-edge platforms and differentiated assets, and supporting companies in expanding their geographic footprints.

• Corporate Strategy and Competitive Analysis: Providing strategic reviews and projections on specific therapeutic areas, analyzing competitive landscapes, and offering recommendations on R&D, clinical development, and commercialization strategies.

• Mergers and Acquisitions: Offering buy-side and sell-side transaction advisory services for healthcare companies, ranging from millions to billions in deal value.

Areas of Specialization

CTIC Capital specializes in cross-border business development, focusing on facilitating partnerships and investments between U.S. and Chinese healthcare companies. The firm's expertise spans various therapeutic areas, including oncology, cardiology, and rare diseases, among others.

Key Technologies Utilized

While specific proprietary technologies are not detailed, CTIC Capital employs advanced data analytics and market intelligence tools to inform strategic decisions and identify growth opportunities for its clients.

Primary Markets Targeted

The firm primarily targets the U.S. and Chinese healthcare markets, facilitating cross-border collaborations and investments. Additionally, CTIC Capital engages in global markets, leveraging its international presence to support clients' expansion strategies.

Financials and Funding

Funding History

As a privately held firm, CTIC Capital has not publicly disclosed detailed financial information or funding history. The firm's operations are supported by its partners' extensive networks and expertise, enabling it to offer a wide range of services without external funding.

Utilization of Capital

The capital generated through its advisory services is reinvested into expanding the firm's capabilities, enhancing its service offerings, and supporting the growth initiatives of its clients.

Pipeline Development

CTIC Capital does not develop its own products or therapies; instead, it focuses on facilitating the development and commercialization of its clients' pipelines. The firm has been involved in several notable collaborations, including:

• METiS Therapeutics and Voronoi License Agreement: In September 2022, METiS Therapeutics entered into a license agreement with Voronoi, Inc., facilitated by CTIC Capital, to develop and commercialize Voronoi’s pan-RAF inhibitor program worldwide.

• BioNTech and OncoC4 Collaboration: In March 2023, BioNTech SE and OncoC4, Inc. announced an exclusive worldwide license and collaboration agreement to develop and commercialize OncoC4’s anti-CTLA-4 monoclonal antibody candidate, ONC-392, in various cancer indications.

• Seagen and Zai Lab License Agreement: In September 2022, Seagen Inc. and Zai Lab Limited announced an exclusive collaboration and license agreement for the development and commercialization of TIVDAK® (tisotumab vedotin-tftv) in mainland China, Hong Kong, Macau, and Taiwan.

Technological Platform and Innovation

Proprietary Technologies

CTIC Capital does not develop proprietary technologies; rather, it leverages its extensive networks and market intelligence to identify and facilitate strategic partnerships and investments for its clients.

Significant Scientific Methods

The firm employs advanced data analytics and market intelligence tools to inform strategic decisions, identify growth opportunities, and support the commercialization efforts of its clients.

Leadership Team

Key Executives

• Yanhong Lin, MBA: Founder and Managing Partner based in Chicago.

• Liangsu Wang, Ph.D.: Partner based in San Francisco.

• Louie Naumovski, M.D., Ph.D.: Partner based in San Francisco.

• Peter Ho, Ph.D., MBA: Partner based in San Francisco.

• Wai T. Wong, M.D., Ph.D.: Partner based in San Francisco.

• Richard Zhao, MBA: Partner based in Shanghai.

• Vicky Shih, Ph.D.: Partner based in Taipei.

• Clarence Kho, MBA: Managing Director based in Hong Kong.

Leadership Changes

No significant leadership changes have been publicly disclosed in recent times.

Competitor Profile

Market Insights and Dynamics

The global healthcare consulting market is characterized by a growing demand for cross-border collaborations, particularly between the U.S. and China. This demand is driven by the need for innovative solutions, access to diverse markets, and the commercialization of technological advancements. CTIC Capital's strategic focus positions it well to capitalize on these market dynamics.

Competitor Analysis

CTIC Capital operates in a competitive landscape with several firms offering similar services. Notable competitors include:

• Ajax Health: A healthcare investment firm focusing on early-stage medical device companies.

• MedPharma Partners: A consulting firm specializing in pharmaceutical and biotechnology sectors.

• Jaunt: A company providing strategic advisory services in the healthcare industry.

CTIC Capital differentiates itself through its extensive cross-border network, particularly between the U.S. and China, and its comprehensive suite of services tailored to the biotech and medtech sectors.

Strategic Collaborations and Partnerships

The firm has facilitated several significant collaborations, including:

• METiS Therapeutics and Voronoi License Agreement: Facilitated by CTIC Capital, this agreement enables METiS to develop and commercialize Voronoi’s pan-RAF inhibitor program worldwide.

• BioNTech and OncoC4 Collaboration: CTIC Capital played a role in facilitating this exclusive worldwide license and collaboration agreement to develop and commercialize ONC-392 in various cancer indications.

• Seagen and Zai Lab License Agreement: CTIC Capital facilitated this exclusive collaboration and license agreement for the development and commercialization of TIVDAK® in specific Asian markets.

Operational Insights

CTIC Capital's strategic collaborations and partnerships enhance its market position by leveraging its extensive networks and expertise to facilitate high-value transactions. The firm's focus on cross-border collaborations, particularly between the U.S. and China, provides a distinct competitive advantage in the healthcare consulting sector.

Strategic Opportunities and Future Directions

Strategic Roadmap

CTIC Capital aims to expand its global footprint by strengthening its presence in key markets and enhancing its service offerings. The firm plans to leverage its cross-border expertise to facilitate more collaborations between U.S. and Chinese healthcare companies, focusing on emerging therapeutic areas and innovative technologies.